Clinical Trial Results:
Does progesterone prophylaxis to prevent preterm labour improve outcome? - a randomised double blind placebo controlled trial (OPPTIMUM)
Summary
|
|
EudraCT number |
2007-007950-77 |
Trial protocol |
GB SE |
Global end of trial date |
31 Dec 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
05 Jul 2020
|
First version publication date |
05 Jul 2020
|
Other versions |
|
Summary report(s) |
Publication |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
OPPTIMUM
|
||
Additional study identifiers
|
|||
ISRCTN number |
ISRCTN14568373 | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
ETHICS: 08/MREOO/6, UKCRN: 4496, MRC FUNDER: G0700452, Grant No: 84982 - 09/800/27 , MHRA CTA: 22931/0009/001-0001 revised by MHRA to 01384/0208/ | ||
Sponsors
|
|||
Sponsor organisation name |
University of Edinburgh
|
||
Sponsor organisation address |
47 Little France Crescent, Edinburgh, United Kingdom, EH16 4TJ
|
||
Public contact |
Marise Bucukoglu, University of Edinburgh, marise.bucukoglu@ed.ac.uk
|
||
Scientific contact |
Professor Jane Norman, University of Edinburgh, marise.bucukoglu@ed.ac.uk
|
||
Sponsor organisation name |
NHS Lothian
|
||
Sponsor organisation address |
47 Little France Crescent, Edinburgh, United Kingdom, EH16 4TJ
|
||
Public contact |
Dr Heather Charles
Head of Research Governance
NHS Lothian, NHS Lothian, ACCORD@nhslothian.scot.nhs.uk
|
||
Scientific contact |
Dr Heather Charles
Head of Research Governance
NHS Lothian, NHS Lothian, ACCORD@nhslothian.scot.nhs.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
31 Dec 2015
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
31 Dec 2015
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
31 Dec 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
In women at high risk of preterm labour, does prophylactic vaginal natural progesterone, 200mg daily from 22 – 34 weeks gestation, compared to placebo:
|
||
Protection of trial subjects |
We recruited pregnant women who were booked for their delivery at one of the hospitals participating in the study and who met the study eligibility criteria.
Case notes of pregnant women were reviewed for the patient’s potential to participate and eligible patients were informed of the study at routine antenatal appointments or by the research midwife or another member of the hospital or research team by telephone or direct mailing of the participant invitation or the current patient information sheet.
Women given information about the study were offered at least 24 hours to read the patient information sheet and invited to consider participation.
|
||
Background therapy |
All women fulfilling the inclusion criteria and consented were tested for fetal fibrenectin (ffn). Those with a positive screening (fFN) test between 22+0 and 24+0 weeks, were eligible for randomisation. Additionally, those who have a previous spontaneous labour resulting in a preterm birth ≤ 34 weeks gestation (by any mode) or short cervix in index pregnancy, defined as cervical length ≤ 25mm were eligible for randomisation to progesterone or placebo even with a negative fFN test. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
03 Dec 2008
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Sweden: 7
|
||
Country: Number of subjects enrolled |
United Kingdom: 1221
|
||
Worldwide total number of subjects |
1228
|
||
EEA total number of subjects |
1228
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
1228
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||
Recruitment details |
All eligible women will be invited to participate in this part of the study. The trial will be explained in detail to the patient and any questions they have will be answered. Those who complete the consent form will undergo fibronectin testing at 22+0 to 24+0weeks gestation. | |||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||
Screening details |
Period 1: 5833 pregnant women were tested for fibronectin. 4605 were excluded from randomisation 1228 were randomised to either progesterone or matching placebo. Period 2: We assesed Neonatal outcomes 1176 babies of women randomised and who were willing. Period 3 We conducted 919 childhood assesments age 2 years of women randomised. | |||||||||||||||||||||
Period 1
|
||||||||||||||||||||||
Period 1 title |
Obstetric phase
|
|||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Carer, Assessor | |||||||||||||||||||||
Blinding implementation details |
The IMP (progesterone) was supplied free of charge to all sites, directly by the manufacturer, Laboratories Besins International. Placebo capsules were identical to active treatment.
|
|||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||
Arm title
|
Progesterone | |||||||||||||||||||||
Arm description |
Utrogestan (Progesterone) 200mg soft capsules | |||||||||||||||||||||
Arm type |
Active comparator | |||||||||||||||||||||
Investigational medicinal product name |
Progesterone
|
|||||||||||||||||||||
Investigational medicinal product code |
PL16468/0001
|
|||||||||||||||||||||
Other name |
Uterogestan
|
|||||||||||||||||||||
Pharmaceutical forms |
Pessary
|
|||||||||||||||||||||
Routes of administration |
Vaginal use
|
|||||||||||||||||||||
Dosage and administration details |
Utrogestan (Progesterone) 200 mg soft capsules or placebo will be prescribed at Visit 2 to be inserted once daily vaginally at bedtime for up to 12 weeks.
|
|||||||||||||||||||||
Arm title
|
Placebo | |||||||||||||||||||||
Arm description |
Placebo pessary | |||||||||||||||||||||
Arm type |
Placebo | |||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Pessary
|
|||||||||||||||||||||
Routes of administration |
Vaginal use
|
|||||||||||||||||||||
Dosage and administration details |
200mg Matching placebo dministered once daily
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Period 2
|
||||||||||||||||||||||
Period 2 title |
Neonatal
|
|||||||||||||||||||||
Is this the baseline period? |
No | |||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||
Roles blinded |
Investigator, Monitor, Data analyst, Carer, Subject, Assessor | |||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
No
|
|||||||||||||||||||||
Arm title
|
Progesterone | |||||||||||||||||||||
Arm description |
Utrogestan (Progesterone) 200mg soft capsules | |||||||||||||||||||||
Arm type |
Active comparator | |||||||||||||||||||||
Investigational medicinal product name |
Progesterone
|
|||||||||||||||||||||
Investigational medicinal product code |
PL16468/0001
|
|||||||||||||||||||||
Other name |
Uterogestan
|
|||||||||||||||||||||
Pharmaceutical forms |
Pessary
|
|||||||||||||||||||||
Routes of administration |
Vaginal use
|
|||||||||||||||||||||
Dosage and administration details |
Utrogestan (Progesterone) 200 mg soft capsules or placebo will be prescribed at Visit 2 to be inserted once daily vaginally at bedtime for up to 12 weeks.
|
|||||||||||||||||||||
Arm title
|
Placebo | |||||||||||||||||||||
Arm description |
Placebo pessary | |||||||||||||||||||||
Arm type |
Placebo | |||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Pessary
|
|||||||||||||||||||||
Routes of administration |
Vaginal use
|
|||||||||||||||||||||
Dosage and administration details |
200mg Matching placebo dministered once daily
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Period 3
|
||||||||||||||||||||||
Period 3 title |
Paediatric
|
|||||||||||||||||||||
Is this the baseline period? |
No | |||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Carer, Assessor | |||||||||||||||||||||
Blinding implementation details |
Women were Blinded. Treatment was not unblinded throughout the follow up period
|
|||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
No
|
|||||||||||||||||||||
Arm title
|
Progesterone | |||||||||||||||||||||
Arm description |
Utrogestan (Progesterone) 200mg soft capsules | |||||||||||||||||||||
Arm type |
Active comparator | |||||||||||||||||||||
Investigational medicinal product name |
Progesterone
|
|||||||||||||||||||||
Investigational medicinal product code |
PL16468/0001
|
|||||||||||||||||||||
Other name |
Uterogestan
|
|||||||||||||||||||||
Pharmaceutical forms |
Pessary
|
|||||||||||||||||||||
Routes of administration |
Vaginal use
|
|||||||||||||||||||||
Dosage and administration details |
Utrogestan (Progesterone) 200 mg soft capsules or placebo will be prescribed at Visit 2 to be inserted once daily vaginally at bedtime for up to 12 weeks.
|
|||||||||||||||||||||
Arm title
|
Placebo | |||||||||||||||||||||
Arm description |
Placebo pessary | |||||||||||||||||||||
Arm type |
Placebo | |||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Pessary
|
|||||||||||||||||||||
Routes of administration |
Vaginal use
|
|||||||||||||||||||||
Dosage and administration details |
200mg Matching placebo dministered once daily
|
|||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Progesterone
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Utrogestan (Progesterone) 200mg soft capsules | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Placebo pessary | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Progesterone
|
||
Reporting group description |
Utrogestan (Progesterone) 200mg soft capsules | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Placebo pessary | ||
Reporting group title |
Progesterone
|
||
Reporting group description |
Utrogestan (Progesterone) 200mg soft capsules | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Placebo pessary | ||
Reporting group title |
Progesterone
|
||
Reporting group description |
Utrogestan (Progesterone) 200mg soft capsules | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Placebo pessary |
|
|||||||||||||
End point title |
Fetal Death or delivery before 34 weeks’ gestation | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Birth/ Delivery
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Death or delivery before 34 weeks’ gestation | ||||||||||||
Comparison groups |
Progesterone v Placebo
|
||||||||||||
Number of subjects included in analysis |
1228
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other [1] | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Regression, Linear | ||||||||||||
Confidence interval |
|||||||||||||
Notes [1] - Intention to treat |
|
|||||||||||||
End point title |
Death, brain injury or severe chronic lung disease | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Neonatal period
|
||||||||||||
|
|||||||||||||
Notes [2] - Nobs (Nmiss) 589 (27) No, n (%) 543 (92.2) Yes, n (%) 46 (7.8) [3] - Nobs, n 587 (23) NO, n (%) 525 (89.4) YES, n (%) 62 (10.6) |
|||||||||||||
Statistical analysis title |
Death or delivery before 34 weeks’ gestation | ||||||||||||
Comparison groups |
Progesterone v Placebo
|
||||||||||||
Number of subjects included in analysis |
1176
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other [4] | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Regression, Linear | ||||||||||||
Confidence interval |
|||||||||||||
Notes [4] - Intention to Treat |
|
|||||||||||||
End point title |
Bayley-III cognitive composite score at 2 years | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Age 2 years (adjusted)
|
||||||||||||
|
|||||||||||||
Notes [5] - Nobs (Nmiss) 410 (206) Mean (SD) 99.7 (14.7) Median (IQR) 100.0 (90.0–110.0) [6] - Nobs (Nmiss) 423 (187) Mean (SD) 99.5 (15.0) Median (IQR) 100.0 (90.0–105.0) |
|||||||||||||
Statistical analysis title |
Bayley-III cognitive composite score at 2 years | ||||||||||||
Comparison groups |
Progesterone v Placebo
|
||||||||||||
Number of subjects included in analysis |
833
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other [7] | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Regression, Linear | ||||||||||||
Confidence interval |
|||||||||||||
Notes [7] - Intention to treat |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
Recorded from the time a participant is randomized to treatment until 30 days after stopping taking study drug (study observational visit) and until pregnancy outcome (28 days after delivery.
|
||
Assessment type |
Systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
MedDRA | ||
Dictionary version |
0
|
||
Frequency threshold for reporting non-serious adverse events: 5% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: The Investigators were requested to review all documentation (e.g. hospital notes, laboratory and diagnostic reports) and record all relevant information in the patient notes, the eCRF only if the AE meets the criteria of serious was it reported to the Sponsors. |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
01 Feb 2008 |
Ethics requested updates to docs in appoval letter
|
||
21 Apr 2008 |
Change sponsor
|
||
22 Sep 2008 |
Protocol redesigned layout to comply with NEW sponsor requirements
|
||
03 Jun 2009 |
Clarification of inclusion/exclusion criteria and items previously noted as TBC included. |
||
15 Oct 2009 |
Correction of Typographical errors including the inclusion criteria which should have been aged16 as per previous ethics documentation. Removal of stratification Para 5.5
|
||
07 Apr 2010 |
Change in IMP excipient, |
||
01 Jun 2010 |
Change to exclusion criteria and identifying patients
|
||
12 Jul 2010 |
To expand recruitment criteria (including fFN-ve women)
|
||
24 Apr 2011 |
Change exclusion, |
||
16 Feb 2012 |
Background literature updated, Information on pilot studies removed
Para 9.1 Sample size revised to 1250
Para 9.2.2 Deletion of formal plan for Health economic analysis (although collection of some economic data remains part of the study protocol)
|
||
04 Oct 2013 |
Revised Protocol V15_04 October 2013 to amend paras 7.2.7 Neonatal/Child Assessments (Section: ‘Child Assessment (at 2 years +/- 8 weeks)’
|
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/29945711 http://www.ncbi.nlm.nih.gov/pubmed/26921136 http://www.ncbi.nlm.nih.gov/pubmed/22866909 |